Back to results
US 7,247,474 B2Granted
Monoclonal antibody which specifically binds to but does not activate the CD8+ cells
AssigneeOrtho-McNeil Pharmaceutical, Inc.
InventorDidier Leturcq
Life of this patent
Estimating the term…
Abstract
This invention provides a method of isolating CD8+ cells which employs an antibody which specifically binds to CD8 molecules present on the surface of CD8+ cells but does not activate the CD8+ cells once bound. This invention also provides related hybridoma cell lines, monoclonal antibodies, antigenic polypeptides, isolated CD8+ cells, and kits.
Claims2
A hybridoma cell line selected from the group consisting of the cell line designated 37B1 (ATCC Accession No. HB-1244) and the cell line designated 8G6 (ATCC Accession No. HB-12657).
Dependencies are inferred from the claim text.